Premium
A small chimeric promoter for high prostate‐specific transgene expression from adenoviral vectors
Author(s) -
Kraaij Robert,
van der Weel Laura,
de Ridder Corrina M.A.,
van der Korput Hetty A.G.M.,
Zweistra Joke L.M.,
van Rijswijk Angélique L.C.T.,
Bangma Chris H.,
Trapman Jan
Publication year - 2007
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.20560
Subject(s) - transgene , prostate cancer , enhancer , prostate , fusion gene , viral vector , biology , promoter , prostate specific antigen , cancer research , microbiology and biotechnology , gene expression , gene , cancer , recombinant dna , genetics
BACKGROUND Specificity of transgene expression is important for safety during gene therapeutical applications. For prostate cancer, transcriptional targeting has been applied but was hampered by loss of specificity and low activity. We constructed a small chimeric promoter for high and prostate‐specific transgene expression from adenoviral vectors. METHODS A chimeric promoter, composed of the prostate‐specific antigen (PSA) enhancer and the rat probasin promoter, was cloned into an adenoviral vector and its activity was compared to vectors containing conventional prostate‐specific promoters and the constitutive Cytomegalovirus (CMV) promoter in in vitro and in vivo prostate cancer models. RESULTS The chimeric PSA‐probasin promoter was the most active prostate‐specific promoter reaching up to 20% of CMV promoter activity while maintaining prostate‐specificity. CONCLUSIONS The chimeric PSA‐probasin promoter is a small promoter that can be utilized in viral vectors for high prostate‐specific transgene expression. Prostate 67: 829–839, 2007. © 2007 Wiley‐Liss, Inc.